Archive
145 evidence-based reports across medicine, nutrition, mental well-being, chronic conditions, and healthcare technology.
Showing 12 of 145 stories · page 5 of 13
Shingrix has long been recommended from age 50, but more younger adults with risk factors are getting it. Here is who should consider it and why timing matters.
The FDA approved suzetrigine (Journavx) in January 2025 as the first new-class non-opioid pain pill in decades. Here is how it works, who it helps, and its limits.
Testosterone prescriptions are climbing as the 2023 TRAVERSE trial cleared major cardiac fears. Here is what the evidence shows, who benefits, and the real remaining risks.
Routine vitamin D supplementation for healthy adults lacks strong proof of benefit. Here is who actually needs testing and treatment, and who is wasting money.
Zurzuvae (zuranolone) is a 14-day pill for postpartum depression, a faster alternative to infusion therapy. Here is how it works, who it helps, and what to watch for.
A 2026 analysis says CGMs may complement standard tests for prediabetes detection. Here is who actually benefits from wearing one, what it shows, and what it cannot tell you.
FDA enforcement ended the routine compounding of semaglutide and tirzepatide in 2026. If your cheap telehealth GLP-1 just stopped refilling, here is a safe path to a legal alternative.
Enlicitide (Lipfendra), the first oral PCSK9 inhibitor, won FDA approval in July 2026 and cuts LDL by more than half. Here is who it helps and how it fits with statins.
FDA drug and supplement recalls surged in 2026 — from a TikTok collagen recall to a dabigatran impurity pull. Here is the step-by-step way to check whether your bottle is affected before you take it.
Tirzepatide and orforglipron labels warn that slowed digestion can blunt oral birth control. Here is the backup-window rule every woman on the pill and a GLP-1 needs to know.
Genitourinary syndrome of menopause (GSM) got its first formal guideline in 2025, and vaginal estrogen data link it to fewer infections and hospitalizations. Here is the symptom most women are never told about.
In February 2026 the FDA removed the boxed cardiovascular, breast-cancer, and dementia warnings from six menopausal hormone therapy products. Here is what changed, what did not, and who should still be careful.
